Welcome to our dedicated page for Nuvectis Pharma SEC filings (Ticker: NVCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvectis Pharma, Inc. filings document the regulatory disclosures of a Nasdaq-listed clinical-stage oncology drug developer with common stock registered under the Exchange Act. Recent Form 8-K reports furnish quarterly and annual financial results, corporate updates, and exhibit press releases describing development activity for NXP900 and related operating progress.
Proxy materials cover annual meeting matters, director elections, auditor ratification, board composition, and stockholder voting procedures. Other material-event filings record governance changes such as director appointments, while cover-page disclosures identify Nuvectis as an emerging growth company and list its common stock trading on the Nasdaq Capital Market under NVCT.
Nuvectis Pharma, Inc. reported wider losses for 2025 as it advanced its lead oncology candidate NXP900 through early-stage clinical development. Cash and cash equivalents were $31.6 million as of December 31, 2025, up from $18.5 million a year earlier, mainly from a February 2025 public offering and use of its at-the-market facility.
The company’s net loss was $26.4 million for 2025 compared with $19.0 million in 2024, driven by higher research and development and general and administrative expenses, including $6.0 million of non-cash stock-based compensation and $2.4 million of one-time license milestone fees. Research and development expenses rose to $18.2 million, while general and administrative costs increased to $9.4 million.
Management highlighted progress in the NXP900 program, including an ongoing Phase 1b monotherapy study across selected tumor types and a combination study with osimertinib in EGFR-mutated NSCLC, with a lorlatinib combination in ALK-positive NSCLC pending initiation. The company believes its current cash can fund multiple NXP900 Phase 1b milestones and operations well into the second half of 2027.
Nuvectis Pharma, Inc. files its annual report, outlining a clinical-stage oncology business focused on precision medicines. The lead candidate, NXP900, is an oral SRC/YES1 kinase inhibitor licensed from the University of Edinburgh, with Phase 1a completed and a Phase 1b expansion under way in solid tumors.
The company has ceased clinical development of its other candidate, NXP800, after a Phase 1b study and is assessing possible next steps. As of December 31, 2025, accumulated losses reached $99.7 million, and the company expects continued losses as it advances development, relies on third-party manufacturers, and operates in a heavily regulated and competitive biopharmaceutical environment.
Nuvectis Pharma, Inc. reported that Chief Dev. & Ops. Officer Shay Shemesh received an award of 150,000 shares of restricted common stock on 01/06/2026 at a price of $0 per share.
The restricted shares will vest in equal annual installments over three years beginning on the first anniversary of the grant date, subject to his continued service. After this grant, Shemesh beneficially owns 1,793,068 shares of Nuvectis common stock, including restricted shares, held directly.
Nuvectis Pharma, Inc. reported an equity award to its Chairman and CEO, Ron Bentsur. On 01/06/2026, he was granted 150,000 shares of restricted common stock at a price of $0 per share. These restricted shares will vest in equal annual installments over three years, starting on the first anniversary of the grant date, as long as he continues to serve with the company on each vesting date.
After this grant, Mr. Bentsur beneficially owns 3,675,924 shares of Nuvectis Pharma common stock, held directly, which includes previously granted restricted shares.
Nuvectis Pharma, Inc. reported an equity grant to a senior officer. Chief Science & Business Officer Enrique Poradosu received 150,000 shares of restricted common stock on January 6, 2026, at a stated price of $0 per share, reflecting a compensatory award rather than an open-market purchase.
The 150,000 restricted shares will vest in equal annual installments over three years, beginning on the first anniversary of the grant date, and are conditioned on Mr. Poradosu’s continued service on each vesting date. Following this grant, he beneficially owned 1,806,319 shares of Nuvectis common stock, which includes restricted shares.
Nuvectis Pharma vice president receives new equity grant. Nuvectis Pharma, Inc. reported that its Vice President of Finance, Michael J. Carson, was awarded 61,200 shares of restricted common stock on January 6, 2026. The grant was priced at $0 per share, reflecting a stock award rather than an open-market purchase.
The 61,200 restricted shares will vest in equal annual installments over three years, beginning on the first anniversary of the grant date, and are conditioned on Mr. Carson’s continued service. After this grant, Mr. Carson beneficially owns a total of 200,118 shares of Nuvectis Pharma common stock, including restricted shares.
Nuvectis Pharma (NVCT) reported an insider purchase by Chairman & CEO Ron Bentsur. On 11/05/2025, he bought 5,000 shares of common stock at $5.72 per share (transaction code P). Following the trade, his directly held beneficial ownership totals 3,525,924 shares.
The total includes 676,759 shares of restricted stock, as noted in the footnote. Bentsur is listed as Director, Chairman & CEO, and a 10% Owner, with the reported holdings shown as Direct (D).
Nuvectis Pharma (NVCT) director reported an open-market purchase of 13,000 shares on November 5, 2025 at a weighted average price of $5.79. After the transaction, the director beneficially owned 78,150 shares directly and 415 shares indirectly as custodian for a son. The filing notes the purchase was executed through multiple same-day trades within a price range of $5.77 to $5.81, consolidated as a single line item.
Nuvectis Pharma (NVCT): Director Matthew Kaplan purchased 11,000 shares of common stock on 11/05/2025 in an open‑market transaction coded “P” at a weighted average price of $5.84. Following this trade, he beneficially owns 124,760 shares, held directly.
The filing notes the price was a weighted average across multiple same‑day trades within a $5.81–$5.88 range, and detailed breakdowns are available upon request.
Nuvectis Pharma, Inc. filed an 8‑K to furnish a press release providing a corporate update and financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and, as stated, the information is being furnished and not deemed filed under the Exchange Act.
The company’s common stock trades on the Nasdaq Capital Market under the symbol NVCT. The filing also includes the iXBRL cover page as Exhibit 104.
Nuvectis Pharma, Inc. filed an 8‑K to furnish a press release providing a corporate update and financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and, as stated, the information is being furnished and not deemed filed under the Exchange Act.
The company’s common stock trades on the Nasdaq Capital Market under the symbol NVCT. The filing also includes the iXBRL cover page as Exhibit 104.